论文部分内容阅读
目的观察贝前列素钠治疗X综合征的治疗效果。方法选取X综合征患者56例,随机分为观察组和对照组,每组28例。对照组予以常规治疗,观察组加用贝前列素钠治疗。于治疗前和治疗1个月后、3个月后、6个月后分别评估患者胸痛程度及频率、运动负荷试验,观察2组患者不良反应发生情况。结果治疗6个月后,观察组胸痛缓解有效率高于对照组,差异有统计学意义(P<0.05)。治疗6个月后,观察组较对照组运动负荷试验中缺血阈值提高,差异有统计学意义(P<0.05)。观察组治疗1个月后较治疗前缺血阈值比较差异无统计学意义(P>0.05),治疗3个月及6个月后较治疗前缺血阈值均有提高,差异有统计学意义(P<0.05)。观察组中未见有出血、休克、间质性肺炎等严重不良反应发生,对照组中有2例出现颜面潮红症状。结论贝前列素钠可在常规冠心病治疗的基础上进一步改善X综合征患者胸痛症状,提高X综合征患者缺血阈值,是治疗X综合征的有效药物。
Objective To observe the therapeutic effect of beraprost sodium on syndrome X. Methods 56 patients with syndrome X were randomly divided into observation group and control group with 28 cases in each group. The control group was given routine treatment, the observation group plus beraprost sodium treatment. Before treatment and after 1 month, 3 months, 6 months after the assessment of chest pain and frequency of patients, exercise stress test to observe the incidence of adverse reactions in two groups. Results After 6 months of treatment, the effective rate of relieving chest pain in the observation group was higher than that of the control group (P <0.05). After 6 months of treatment, the ischemic threshold increased in the exercise stress test in the observation group compared with that in the control group, with a significant difference (P <0.05). There was no significant difference in the threshold of ischemia after 1 month of treatment in observation group (P> 0.05), and the threshold of ischemia after 3 months and 6 months of treatment was higher than that before treatment (P <0.05), the difference was statistically significant P <0.05). In the observation group, no serious adverse reactions such as hemorrhage, shock and interstitial pneumonia occurred. In the control group, there were 2 cases of facial flushing. Conclusion Beraprost sodium can further improve chest pain symptoms in patients with syndrome X and improve ischemic threshold in patients with syndrome X. It is an effective drug for the treatment of syndrome X on the basis of conventional treatment of coronary heart disease.